DexCom vs Roivant Sciences
DexCom (DXCM), health care, and Roivant Sciences (ROIV), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
DexCom is worth $30.6B on the stock market and Roivant Sciences $28B: DexCom is valued at 9% more. DexCom's operating margin in its latest fiscal year was 19.6% and Roivant Sciences's -6236%. Over the past year DexCom's share price has moved +35.6% and Roivant Sciences's +88.2%.
Key facts
- DexCom market value
- $30.6B
- Roivant Sciences market value
- $28B
- DexCom P/E
- 32.2
- DexCom revenue
- $4.7BFY to 2025-12-31
- Roivant Sciences revenue
- $8.3MFY to 2026-03-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | DexCom | Roivant Sciences |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size | ||
| Market cap | $30.6Bhigher | $28Blower |
| Revenue | $4.7Bhigher | $8.3Mlower |
| Earnings | $836.3Mhigher | -$299.8Mlower |
| Employees | 11,000higher | 721lower |
| Total assets | $6.3Bhigher | $5.7Blower |
| Valuation | ||
| P/E | 32.2 | — |
| P/S | 6.6lower | 3396higher |
| P/B | 12.1 | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | 19.6%higher | -6236%lower |
| Balance sheet | ||
| Net assets | $2.7Blower | $4.5Bhigher |
| Total liabilities | $3.6Bhigher | $416.3Mlower |
| Total debt | — | — |
| Cash on hand | $917.7Mlower | $1.4Bhigher |
| Price change | ||
| Today | +0.53%higher | +0.26%lower |
| 1 year | +35.6%lower | +88.2%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
DexCom only (2)
Roivant Sciences only (6)
- Andrew Spokes4.1%
- David Einhorn1.9%
- Lee Ainslie0.9%
- Julian and Felix Baker0.8%
- Andreas Halvorsen0.6%
- Steve Cohen0.2%
Percentages are each holding's share of that investor's reported portfolio. Who owns DXCM · Who owns ROIV
More on DexCom
Further comparisons
DexCom against its closest peers
Roivant Sciences against its closest peers
Learn
Questions and answers
Which is bigger, DexCom or Roivant Sciences?
By market value, DexCom is the larger: $30.6B against $28B for Roivant Sciences. By revenue in its latest fiscal year, DexCom is the larger: $4.7B against $8.3M for Roivant Sciences.
Which has the higher operating margin?
DexCom: 19.6%, against -6236% for Roivant Sciences. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both DexCom and Roivant Sciences?
None of the tracked superinvestors holds both in their latest 13F filing. 2 hold DexCom and 6 hold Roivant Sciences.
Cite this page
Funkfolio, “DexCom vs Roivant Sciences”, data as of 18 November 2026. https://funkfolio.com/compare/dxcm-vs-roiv
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.